Regenerative Medicine Leads The Market

Gene therapy the most valuable regenerative medicine (RM) segment is forecast to reach $13.3 billion by 2026, as RM is a rapidly expanding field, according to a report ‘Regenerative Medicine in Pharma – Thematic Research’ at GlobalData, a leading data and analytics company. There are currently 53 marketed RM products and 175 RM pipeline agents in development in the eight major markets (8MM*). Among the gene therapy market, Novartis’ Zolgensma is expected to lead the market. With the continued expansion and benefits obtained by patients from these markets, the growth is being expected at a greater phase.

Regenerative Medicine Market:

Alessio Brunello, Managing Pharma Analyst at GlobalData, comments: “The COVID-19 pandemic could be an opportunity for the companies pursuing the development of gene therapies, a few products are in development to fight the viral illness. However, challenges are still present for gene therapies, as these types of therapies need to produce enough evidence of proven safety and also a better efficacy comparing with already marketed products, such as antiviral drugs.”

Joining the race, even the cell therapy field especially, the CAR-T therapies in oncology, such as Novartis’ Kymriahis rising but lack of data and manufacturing are barriers for this sector. The cell therapy market was valued at $121m in 2019 in the 8MM and is forecast to reach $3.1bn by 2026.The establishment of their manufacturing process across various regions along with off-the-shelf solutions has its limitations and struggles.

“Special designations and programs exist across the 8MM, which expediate the development and approval of regenerative medicines. However, the high cost of certain products, such as gene therapies, could hinder their adoption and accessibility for patients”, adds Brunello.

Source-Medindia